Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 10/20 | 0.63 |
| ▸ | PTGS1 | P23219 | 8/20 | 0.57 |
| ▸ | CA1 | P00915 | 6/20 | 0.55 |
| ▸ | CA2 | P00918 | 6/20 | 0.55 |
| ▸ | CA4 | P22748 | 6/20 | 0.55 |
| ▸ | CA9 | Q16790 | 6/20 | 0.55 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8636808 | 0.83 | PTGS2 (0.74) | PTGS2PTGS1CA1CA2CA4 | |
| SCHEMBL6341812 | 0.82 | PTGS2 (0.71) | PTGS2PTGS1CA1CA2CA4 | |
| SCHEMBL6353455 | 0.81 | PTGS2 (0.70) | PTGS2PTGS1CA1CA2CA4 | |
| SCHEMBL6349532 | 0.80 | PTGS2 (0.69) | PTGS2PTGS1CA1CA2CA4 | |
| SCHEMBL6353959 | 0.80 | PTGS2 (0.74) | PTGS2PTGS1CA1CA2CA4 | |
| SCHEMBL6351372 | 0.79 | PTGS2 (0.67) | PTGS2PTGS1CA1CA2CA4 | |
| SCHEMBL6341478 | 0.78 | PTGS2 (0.79) | PTGS2PTGS1CA1CA2CA4 | |
| SCHEMBL6339325 | 0.78 | PTGS2 (1.00) | PTGS2PTGS1CA1CA2CA4 | |
| SCHEMBL6350079 | 0.76 | PTGS2 (0.79) | PTGS2PTGS1CA1CA2CA4 | |
| SCHEMBL8981180 | 0.76 | PTGS2 (0.74) | PTGS2PTGS1CA1CA2CA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090099139-A1 | NITROSATED AND NITROSYLATED CYCLOOXYGENASE-2 INHIBITORS, COMPOSITIONS AND METHODS OF USE | NITROMED, INC. (US) | 2009-04-16 | — | — | US | disclosed |
| US-7432285-B2 | Nitrosated and nitrosylated cyclooxygenase-2 inhibitors, compositions and methods of use | NITROMED, INC. (US) | 2008-10-07 | — | — | US | disclosed |
| US-20070060571-A1 | Nitrosated and nitrosylated cyclooxygenase-2 inhibitors, compositions and methods of use | NITROMED, INC. (US) | 2007-03-15 | — | — | US | disclosed |
| US-7166618-B2 | Nitrosated and nitrosylated cyclooxygenase-2 inhibitors, compositions and methods of use | NITROMED, INC. (US) | 2007-01-23 | — | — | US | disclosed |
| US-20030220228-A1 | Nitrosated and nitrosylated cyclooxygenase-2 inhibitors, compositions and methods of use | NICOX S.A. (FR) | 2003-11-27 | — | — | US | disclosed |
| US-6649629-B2 | 4-(5-(4-chlorophenyl)-3-((nitrooxy)methyl)-3-hydropyrazolyl) -benzenesulfonamide, for example; treating gastrointestinal disorders, ulcer healing agents, treating disorders resulting from elevated cyclooxygenase (COX-2) | NITROMED, INC. | 2003-11-18 | — | — | US | disclosed |
| US-20010041726-A1 | 4-(5-(4-chlorophenyl)-3-((nitrooxy)methyl)-3-hydropyrazolyl) -benzenesulfonamide, for example; treating gastrointestinal disorders, ulcer healing agents, treating disorders resulting from elevated cyclooxygenase (COX-2) | NICOX S.A. (FR) | 2001-11-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099139-A1 | NITROSATED AND NITROSYLATED CYCLOOXYGENASE-2 INHIBITORS, COMPOSITIONS AND METHODS OF USE | NOS2, PTGS2, PTGIS | PTGS2 2/4885PTGS1 5/4885CA1 2810/4885 |
| US-20070060571-A1 | Nitrosated and nitrosylated cyclooxygenase-2 inhibitors, compositions and methods of use | NOS2, PTGS2, PTGIS | PTGS2 2/4885PTGS1 5/4885CA1 2810/4885 |
| US-20030220228-A1 | Nitrosated and nitrosylated cyclooxygenase-2 inhibitors, compositions and methods of use | PTGS2, PTGS1, PTGES2 | PTGS2 1/4885PTGS1 2/4885CA1 4582/4885 |
| US-20010041726-A1 | 4-(5-(4-chlorophenyl)-3-((nitrooxy)methyl)-3-hydropyrazolyl) -benzenesulfonamide, for example; treating gastrointestinal disorders, ulcer healing agents, treating disorders resulting from elevated cyclooxygenase (COX-2) | PTGS1, PTGS2, PTGES | PTGS2 2/4885PTGS1 1/4885CA1 4745/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.